These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 26401644)
1. Refractory Gestational Trophoblastic Neoplasia: A Novel Drug Combination With Paclitaxel and Carboplatin Produces Durable Complete Remission. Rathod PS; Kundargi R; Pallavi VR; Vijay CR; Devi UK; Bafna UD Int J Gynecol Cancer; 2015 Nov; 25(9):1737-41. PubMed ID: 26401644 [TBL] [Abstract][Full Text] [Related]
2. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia]. Song SQ; Zhang GN Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175 [TBL] [Abstract][Full Text] [Related]
3. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia]. Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278 [No Abstract] [Full Text] [Related]
4. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Mao Y; Wan X; Lv W; Xie X Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633 [TBL] [Abstract][Full Text] [Related]
5. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709 [TBL] [Abstract][Full Text] [Related]
6. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India. Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171 [TBL] [Abstract][Full Text] [Related]
7. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004 [TBL] [Abstract][Full Text] [Related]
8. Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017. Zhu CC; Liu HY; Wei Y; Shen Z; Qian LL; Song WG; Wang J; Wu DB; Zhang XF; Zhou Y Taiwan J Obstet Gynecol; 2019 May; 58(3):332-337. PubMed ID: 31122520 [TBL] [Abstract][Full Text] [Related]
13. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528 [TBL] [Abstract][Full Text] [Related]
14. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia. Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033 [TBL] [Abstract][Full Text] [Related]